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patients with IHCA and is associated with a lower probabil-
ity of survival in the subgroup of patients with asystole or
PEA.
Perspective: The factors that determined whether an AED was
used in these patients are unclear, and it is possible that hos-
pital personnel less skilled in cardiopulmonary resuscitation
were more likely to use an AED. This could be a reason that
AEDs were associated with lower survival in patients with
nonshockable rhythms. It is also possible that the time
required for electrode placement and automatic rhythm
analysis by the AED delayed the onset of chest compressions.   
Summary written by: Fred Morady, MD
Cost-Effectiveness of Dabigatran Compared With
Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman JV, Zhu RP, Owens DK, et al.
Ann Intern Med 2010;Nov 1:[Epub ahead of print].
Study Question: Is dabigatran cost-effective relative to warfarin
for stroke prevention in patients with atrial fibrillation (AF)
and risk factors for stroke? 
Methods: A Markov decision model in patients 65 years or
older was used to determine cost-effectiveness based on data
published in clinical trials and pricing in the United
Kingdom. Warfarin therapy was compared to dabigatran at
daily dosages of 220 and 300 mg. The outcome measures
were quality-adjusted life-years (QALYs), net costs over 35
years or until death in 2008 dollars, and incremental cost-
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Arrhythmias
Automated External Defibrillators and Survival
After In-Hospital Cardiac Arrest
Chan PS, Krumholz HM, Spertus JA, et al.
JAMA 2010;304:2129–2136.
Study Question: Does use of automated external defibrillators
(AEDs) improve survival after in-hospital cardiac arrest
(IHCA)?  
Methods: Review of the National Registry of
Cardiopulmonary Resuscitation identified 11,695 patients
(mean age 68.6 years) from 204 hospitals at which AEDs
were available for use in patients with IHCA. Nonshockable
rhythms were defined as asystole or pulseless electrical activ-
ity (PEA), and shockable rhythms were defined as
ventricular tachycardia or ventricular fibrillation. The pri-
mary outcome was survival to hospital discharge.
Results: The first recorded rhythm during the IHCAs was
shockable in 17.8% of patients. The AED was used in 38.6%
of patients. Among the patients with a shockable rhythm,
survival to hospital discharge was not significantly different
when the AED was used (38.4%) than when it was not used
(39.8%). In patients with a nonshockable rhythm, AED use
was independently associated with a 26% lower probability of
survival to hospital discharge (10.4% with AED vs. 15.4%
without AED).
Conclusions: The use of AEDs does not improve survival in
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reported AF-related genetic variants. Premature familial AF
was associated with improved discrimination beyond traditional
risk factors to the greatest extent. Modest changes in integrated
discrimination improvement were observed with premature
familial AF (2.1%). Net reclassification improvement did not
change significantly with premature familial AF (index statis-
tic, 0.011; p = 0.51), although categoryless net reclassification
was improved (index statistic, 0.127; p = 0.009).
Conclusions: Familial AF was associated with an increased risk
of AF that was not attenuated by adjustment for AF risk fac-
tors including genetic variants.
Perspective: This study reports an association between the
occurrences of AF in a first degree-relative. Familial AF was
associated with new-onset AF after multivariable adjustment
for commonly accepted AF risk factors, including genetic
variants at AF susceptibility loci. Future studies should
attempt to understand the factors that mediate the associa-
tion between familial AF and AF risk, further explore the
relationships between premature familial AF and risk predic-
tion, and determine whether incorporating novel genetic
variants into the model enhances its performance.  
Summary written by: Fred Morady, MD
European Ancestry as a Risk Factor for Atrial
Fibrillation in African Americans 
Marcus GM, Alonso A, Peralta CA, et al., on behalf of the Candidate-
Gene Association Resource (CARe) Study.
Circulation 2010;122:2009–2015.
Study Question: Is European ancestry a risk factor for atrial fib-
rillation (AF)?    
Methods: The study subjects were individuals (15,445 whites,
4,339 African Americans) without a history of AF who par-
ticipated in the Cardiovascular Health Study and the
Atherosclerosis Risk in Communities Study. The percentage
of European ancestry in African Americans was determined
by genetic analysis, and episodes of new-onset AF were
noted during a median follow-up of 10-16 years.
Results: New-onset AF occurred during follow-up in 2,240
individuals. The incidence of AF was 25-35% lower in African
Americans than in whites. After adjustment for other risk fac-
tors, African Americans had a 40-56% lower risk of AF than
whites. The African American subjects had mean European
ancestry of 17-24%. After adjustment for confounding vari-
ables, every 10% increase in European ancestry was associated
with a 17% higher risk of developing AF.
Conclusions: European ancestry is an independent predictor of
new-onset AF.
Perspective: Prior studies also demonstrated a lower incidence
2 Eagle, Cannon
Scanning the Literature
JACC, Vol. 57, No. 1, 2011
December 28, 2010/January 4, 2011:1-8
effectiveness ratios (ICERs).
Results: Life-expectancy was 10.28 QALYs with warfarin,
10.70 QALYs with low-dose dabigatran, and 10.84 QALYs
with high-dose dabigatran. Total costs were $143,193 for
warfarin, $164,576 for low-dose, and $168,398 for high-dose
dabigatran. Relative to warfarin, the ICER was
$51,229/QALY for low-dose and $45,372/QALY for high-
dose dabigatran. The ICER was sensitive to cost, with the
ICER of high-dose dabigatran increasing to $50,000/QALY
at a daily cost of $13.70.
Conclusions: Dabigatran may be a cost-effective alternative to
warfarin for stroke prevention in patients with risk factors,
depending on pricing.
Perspective: Dabigatran is a direct thrombin inhibitor that has
major advantages over warfarin. It is taken at a fixed daily
dosage, and does not require monitoring of the international
normalized ratio or dietary restrictions. The RE-LY trial
demonstrated a lower risk of stroke, systemic embolism, and
intracranial hemorrhage with high-dose dabigatran compared
to warfarin. Dabigatran at a daily dose of 300 mg was
recently approved by the Food and Drug Administration for
stroke prevention in patients with AF, and should become
available for clinical use in the near future.   
Summary written by: Fred Morady, MD
Association Between Familial Atrial Fibrillation
and Risk of New-Onset Atrial Fibrillation
Lubitz SA, Yin X, Fontes JD, et al.
JAMA 2010;Nov 13:[Epub ahead of print].
Study Question: What is the association between familial atrial
fibrillation (AF) and risk of new-onset AF?   
Methods: The Framingham Heart Study was a prospective
community-based cohort study, which started in 1948.
Original and Offspring Cohort participants were at least 30
years old, were free of AF at baseline examination, and had at
least one parent or sibling enrolled in the study. The 4,421
participants in this analysis (mean age 54 years; 54% women)
were followed up through December 31, 2007. Incremental
predictive value of incorporating different features of familial
AF into a risk model for new-onset AF was analyzed.
Results: Across 11,971 examinations from 1968-2007, 440
participants developed AF. Familial AF occurred among
1,185 participants (26.8%), and premature familial AF
occurred among 351 participants (7.9%). AF occurred more
frequently among participants with familial AF than without
(unadjusted absolute event rates of 5.8% and 3.1%, respec-
tively). The association was not attenuated by adjustment for
AF risk factors (multivariable-adjusted hazard ratio, 1.40) or
Bundle-Branch Block Morphology and Other
Predictors of Outcome After Cardiac
Resynchronization Therapy in Medicare Patients 
Bilchick KC, Kamath S, Dimarco JP, Stukenborg GJ.
Circulation 2010;122:2022–2030.
Study Question: What are the strongest predictors of out-
comes with cardiac resynchronization therapy (CRT)? 
Methods: The study subjects were 14,946 patients (mean age
73 years) in a Medicare implantable cardioverter-defibrillator
(ICD) registry who received a CRT device combined with an
ICD (CRT-D). Medicare data were reviewed for information
on survival and heart failure (HF) hospitalizations.
Results: The mortality rate was 37.2% over a median follow-
up of 40 months and the rate of death or HF hospitalization
was 52.3%. The strongest predictors of death were New York
Heart Association HF class IV (hazard ratio [HR], 1.98), age
≥80 years (HR, 1.75), ischemic cardiomyopathy (HR, 1.44),
and a right bundle branch block (RBBB; HR, 1.37). Relative
to a QRS duration of 120-149 ms, a QRS duration ≥150 ms
was associated with a 14% lower risk of death.
Conclusions: Class IV HF, advanced age, ischemic cardiomy-
opathy, and RBBB are the strongest predictors of death
after CRT-D implantation.
Perspective: The study implies that the presence of one or
more predictors of mortality should raise the threshold for
implantation of a CRT-D. However, the study did not
include a control group of patients with these predictors of
death who did not receive a CRT-D. Therefore, the extent to
which such patients benefit from CRT-D remains unclear.  
Summary written by: Fred Morady, MD
General Cardiology
Docosahexaenoic Acid Supplementation and
Cognitive Decline in Alzheimer Disease: A
Randomized Trial 
Quinn JF, Raman R, Thomas RG, et al.
JAMA 2010;304:1903–1911. 
Study Question: Does supplementation with docosahexaenoic
acid (DHA) slow cognitive and functional decline in individu-
als with Alzheimer disease? 
Methods: A randomized, double-blind, placebo-controlled
trial of DHA supplementation was conducted in individuals
with mild to moderate Alzheimer disease (Mini-Mental
State Examination scores, 14-26) between November 2007
of AF in African Americans than in whites. This seems par-
adoxical, because African Americans have a higher
prevalence of hypertension and heart failure and a larger
mean body mass index than whites. The results of this study
suggest that the racial difference in risk of AF is genetic in
origin. The specific reasons that European ancestry predis-
poses to AF remain to be identified.  
Summary written by: Fred Morady, MD
Cardiac-Resynchronization Therapy for Mild-to-
Moderate Heart Failure
Tang AS, Wells GA, Talajic M, et al.
N Engl J Med 2010;Nov 14:[Epub ahead of print].
Study Question: Does the addition of cardiac resynchroniza-
tion therapy (CRT) to treatment with an implantable
cardioverter-defibrillator (ICD) and optimal medical therapy
improve outcomes in patients with New York Heart
Association (NYHA) class II-III heart failure (HF)?  
Methods: The subjects of the Resynchronization-
Defibrillation for Ambulatory Heart Failure Trial (RAFT)
multicenter study were 1,798 patients (mean age 66 years)
with NYHA class II-III HF, an ejection fraction ≤30%, and
QRS duration ≥120 ms, randomly assigned to receive opti-
mal medical therapy plus an ICD (n = 904) or the same
therapy plus CRT (n = 894). The devices were programmed
to minimize ventricular pacing in the ICD group and to
maximize ventricular pacing in the ICD-CRT group.
Follow-up evaluations were performed regularly over a mean
follow-up of 40 months. The 1º outcome was all-cause mor-
tality or hospitalization for HF. 
Results: Death or HF hospitalization occurred significantly
more often in the ICD (40.3%) than the CRT-ICD group
(33.2%). Compared to the ICD group, there was a relative
reduction of 25% in mortality in the ICD-CRT group, a
24% relative reduction in cardiovascular deaths, and a 32%
relative reduction in HF hospitalizations. Device-related
hospitalizations and lead dislodgement requiring interven-
tion were significantly more prevalent in the ICD-CRT
group (20% and 6.9%, respectively) than in the ICD group
(12.2% and 2.2%, respectively). 
Conclusions: The addition of CRT to an ICD in patients with
NYHA class II-III HF, a wide QRS, and left ventricular dys-
function reduces the rate of death and HF hospitalizations.
Perspective: The importance of this study is that it provides
the first solid evidence that CRT has incremental value with
regard to clinically-relevant outcomes when added to an
ICD implanted for 1º prevention of sudden cardiac death.  
Summary written by: Fred Morady, MD
JACC, Vol. 57, No. 1, 2011
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and May 2009 at 51 US clinical research sites of the
Alzheimer’s Disease Cooperative Study. Patients were ran-
domized to 1 g twice daily of DHA derived from marine
algae or matching placebo.
Results: A total of 402 individuals were randomized and 295
participants completed the trial while taking study medica-
tion (DHA: 171; placebo: 124). Mean age was 76 years,
52% were female, and 23% were smokers. Supplementation
with DHA had no beneficial effect on rate of change on the
Alzheimer’s Disease Assessment Scale (ADAS)-cog score,
which increased by a mean of 7.98 points for the DHA
group during 18 months versus 8.27 points (linear mixed-
effects model: p = 0.41). In the subpopulation of
participants (DHA: 53; placebo: 49), the rate of brain atro-
phy was not affected by treatment with DHA. At 18-month
follow-up, the DHA group had a 1.32% volume decline per
year compared with 1.29% in those on placebo. 
Conclusions: Supplementation with DHA compared with
placebo did not slow the rate of cognitive and functional
decline in patients with mild to moderate Alzheimer disease.
Perspective: Epidemiologic and mouse model studies suggested
that DHA supplement would be helpful in dementia. The
decision to use DHA rather than marine oil containing both
DHA and EPA is based upon the finding that DHA but not
EPA is found in the brain. The benefits of fish oil derived
from diet or supplements include reduction in first and recur-
rent coronary events, reduction in mortality in heart failure,
reduction in sudden death and atrial fibrillation, anti-inflam-
matory, antiplatelet, antidepressant, reduction in triglycerides,
and antiatherosclerotic.  
Summary written by: Melvyn Rubenfire, MD
Primary Results From the SmartDelay Determined
AV Optimization: A Comparison to Other AV Delay
Methods Used in Cardiac Resynchronization
Therapy (SMART-AV) Trial: A Randomized Trial
Comparing Empirical, Echocardiography-Guided,
and Algorithmic Atrioventricular Delay Programming
in Cardiac Resynchronization Therapy 
Ellenbogen KA, Gold MR, Meyer TE, et al.
Circulation 2010;Nov 15:[Epub ahead of print].
Study Question: Are outcomes affected by the method of
determining atrioventricular (AV) delay in cardiac resyn-
chronization therapy (CRT)? 
Methods: A total of 1,014 patients (68% men, mean age 66 ±
11 years, mean left ventricular [LV] ejection fraction 25 ±
7%) who met enrollment criteria in the SMART-AV trial
underwent a CRT defibrillator implantation. Of these, 980
patients were randomized in a 1:1:1 ratio to fixed empirical
AV delay of 120 ms, to echocardiographically optimized AV
delay, or to AV delay optimized with SmartDelay (an elec-
trogram-based algorithm). All patients were programmed
(DDD-60 or DDDR-60) and evaluated after implantation
and 3 and 6 months later. The primary endpoint was LV
end-systolic volume.
Results: The medians (quartiles 1 and 3) for change in LV
end-systolic volume at 6 months for SmartDelay, echocar-
diography, and fixed arms were -21 ml (-45 and 6 ml), -19
ml (-45 and 6 ml), and -15 ml (-41 and 6 ml), respectively.
No difference in improvement in LV end-systolic volume at
6 months was observed between the SmartDelay and
echocardiography arms (p = 0.52) or the SmartDelay and
fixed arms (p = 0.66). Secondary endpoints, including struc-
tural (LV end-diastolic volume and LV ejection fraction)
and functional (6-minute walk, quality of life, and New
York Heart Association classification) measures, were not
significantly different between arms. 
Conclusions: Neither SmartDelay nor echocardiography was
superior to a fixed AV delay of 120 ms. The routine use of
AV optimization techniques assessed in this trial is not war-
ranted. However, these data do not exclude possible utility
in selected patients who do not respond to CRT.
Perspective: This study suggests that specific algorithms for
determining AV delay had no benefit compared to a simple
approach of a fixed AV interval of 120 ms. Differences
between findings in this trial and in other recent trials could
be due to differences in supine versus ambulatory hemody-
namic outcomes, or due to differences between AV
optimization schemes that were too small to be detected or
too small to result in clinical differences. The field of CRT
and methodologies for AV optimization remains in flux. But
if a majority of patients enjoy improvement associated with
CRT, perhaps special attention should be directed to opti-
mization schemes in ‘non-responders.’  
Summary written by: David S.  Bach, MD
Heart Failure/Transplant
Association of Serial Measures of Cardiac Troponin
T Using a Sensitive Assay With Incident Heart
Failure and Cardiovascular Mortality in Older Adults 
deFilippi CR, de Lemos JA, Christenson RH, et al.
JAMA 2010;Nov 15:[Epub ahead of print]. 
Study Question: What is the effect of serial measures of car-
diac troponin T (cTnT) measured by a highly sensitive assay
on the risk of heart failure (HF) hospitalization and cardio-
vascular death? 
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Methods: The BASKET-PROVE investigators randomly
assigned 2,314 patients needing stents that were 3.0 mm or
more in diameter to receive sirolimus-eluting, everolimus-
eluting, or bare-metal stents. The primary endpoint was the
composite of death from cardiac causes or nonfatal myocardial
infarction (MI) at 2 years. Late events (occurring during
months 7-24) and target vessel revascularization (TVR) were
the main secondary endpoints.
Results: The rates of the primary endpoint were 2.6% among
patients receiving sirolimus-eluting stents, 3.2% for
everolimus-eluting, and 4.8% for bare-metal stents, with no
significant differences between patients receiving either DES
or those receiving bare-metal stents. There were also no sig-
nificant between-group differences in the rate of late events
or in the rate of death, MI, or stent thrombosis. Rates of
TVR for reasons unrelated to MI were 3.7% among patients
receiving sirolimus-eluting stents, 3.1% for everolimus-elut-
ing, and 8.9% for bare-metal stents. The rate of TVR was
significantly reduced among patients receiving either DES, as
compared with a bare-metal stent, with no significant differ-
ence between the two types of DES. 
Conclusions: In patients requiring stenting of large coronary
arteries, no significant differences were found among
sirolimus-eluting, everolimus-eluting, and bare-metal stents
with respect to the rate of death or MI, but DES were asso-
ciated with lower TVR.
Perspective: This trial showed no evidence of an increased risk
associated with DES. A clinically relevant reduction in TVR
with DES was confirmed and there was a nonsignificant
reduction in cardiac death and MI, suggesting that if the sam-
ple had been larger, even a reduction in these rates might have
been observed. Overall, the study suggests a significant advan-
tage of DES over bare-metal stents even in larger arteries,
with no apparent differences between first- and second-gener-
ation DES.  
Summary written by: Debabrata Mukherjee, MD
Noninvasive Cardiology
Association of Adolescent Obesity With Risk of
Severe Obesity in Adulthood
The NS, Suchindran C, North KE, Popkin BM, Gordon-Larsen P.
JAMA 2010;304:2042–2047.
Study Question: Does weight during adolescence influence risk
of severe obesity during adulthood?
Methods: Data from the US National Longitudinal Study of
Adolescent Health cohort were used for the present study.
This cohort was comprised of adolescents and young adults
Methods: A longitudinal nationwide cohort study
(Cardiovascular Health Study) of 4,221 community-dwelling
adults ages 65 years or older without prior HF who had
cTnT measured using a highly sensitive assay at baseline
(1989-1990) and repeated after 2-3 years (n = 2,918) was per-
formed. The primary outcome measures were new-onset HF
and cardiovascular death with respect to cTnT concentra-
tions, accounting for clinical risk predictors.
Results: cTnT was detectable (≥3.00 pg/ml) in 2,794 partici-
pants (66.2%). During a median follow-up of 11.8 years,
1,279 participants experienced new-onset HF and 1,103 car-
diovascular deaths occurred, with a greater risk of both
endpoints associated with higher cTnT concentrations.
Among those participants with the highest cTnT concentra-
tions (>12.94 pg/ml), there was an incidence rate per 100
person-years of 6.4 for HF, and 4.8 for cardiovascular death
compared with participants with undetectable cTnT levels.
Among individuals with initially detectable cTnT, a subse-
quent increase of more than 50% (n = 393, 22%) was
associated with a greater risk for HF and cardiovascular death,
and a decrease of more than 50% (n = 247, 14%) was associ-
ated with a lower risk for HF and cardiovascular death
compared with participants with 50% or less change. Addition
of baseline cTnT measurements to clinical risk factors was
associated with only modest improvement in discrimination. 
Conclusions: Baseline cTnT levels and changes in cTnT levels
measured with a highly sensitive assay were significantly
associated with incident HF and cardiovascular death.
Perspective: The observation that changes in cTnT track with
risk of HF and cardiovascular death reflects the dynamic
nature of cardiovascular risk in older adults. Additional studies
are needed to assess whether monitoring low levels of cTnT
may provide an opportunity to motivate specific lifestyle
changes or prompt therapeutic interventions before progres-
sion to symptoms or cardiac structural abnormalities, and to
track clinical outcomes associated with these interventions.  
Summary written by: Debabrata Mukherjee, MD
Interventional Cardiology
Drug-Eluting Versus Bare-Metal Stents in Large
Coronary Arteries
Kaiser C, Galatius S, Erne P, et al., on behalf of the BASKET-PROVE
Study Group.
N Engl J Med 2010:Nov 16:[Epub ahead of print].
Study Question: What is the relative efficacy of first-generation
drug-eluting stents (DES), second-generation DES, and bare-
metal stents placed in large coronary arteries?  
JACC, Vol. 57, No. 1, 2011
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between the ages of 12 and 21 years, who enrolled in wave
II of the study in 1996. Follow-up occurred in 2001-2002
(wave III) when the cohort was age 18-27 years, and 2007-
2009 (wave IV) when the cohort was age 24-33 years.
Height and weight were obtained via anthropometry and
surveys administered in participants’ homes using standard-
ized procedures. The primary outcome of interest was new
cases of adult-onset severe obesity calculated by sex,
race/ethnicity, and adolescent weight status.
Results: A total of 8,834 subjects were included. In 1996, 79
(1.0%) adolescents were severely obese, of which 60 (70.5%)
remained severely obese in adulthood. By 2009, 703 (7.9%)
non–severely obese adolescents had become severely obese
in adulthood. Rates of severe obesity were highest for non-
Hispanic black women. Obese adolescents were
significantly more likely to develop severe obesity in young
adulthood than normal-weight or overweight adolescents
(hazard ratio, 16.0).
Conclusions: Obesity in adolescents is associated with a sig-
nificantly increased risk of severe obesity in adulthood. This
risk appears to vary by sex and race/ethnicity.
Perspective: These data highlight the importance of preventing
weight gain in our children. Further research is warranted to
determine if weight loss among obese adolescents would pre-
vent severe obesity in adulthood.  
Summary written by: Elizabeth Jackson, MD
Multiple Testing, Cumulative Radiation Dose, and
Clinical Indications in Patients Undergoing
Myocardial Perfusion Imaging
Einstein AJ, Weiner SD, Bernheim A, et al.
JAMA 2010:304;2137–2144.
Study Question: What is the number of procedures, cumula-
tive effective radiation doses (ERDs), clinical indications,
and demographic distribution of patients undergoing
myocardial perfusion imaging (MPI)? 
Methods: This was a single-center retrospective study of 1,097
patients (mean age 62.1 years; 51.5% women) who underwent
MPI between January 1 and April 10, 2006. Medical records
were reviewed to identify imaging procedures involving ioniz-
ing radiation from October 1988 to date of the index MPI
and all subsequent procedures through June 2008. Indication
for testing, patient demographics, number of procedures, and
cumulative ERDs were tabulated for outcome.
Results: The median number of procedures was 15, with a
mean of 23.9 ± 26.8 and a range of 1-193. Patients received
a mean and median number of high-dose procedures of 4
and 6.5 and a mean of 1.8 MPI. For the entire cohort, the
median ERD (milliSieverts) was 64.0 and the mean was
95.6 ± 93.1. The mean ERD attributable to MPI was 44.6 ±
34.4 mSv, representing 46% of the mean dose for all proce-
dures. A total of 344 patients (31.4%) received cumulative
ERD >100 mSv and 120 (10.9%) received cumulative ERD
>200 mSv. A cumulative dose of >100 mSv related to MPI
alone was noted in 71 patients (6.5%). For MPI, the indica-
tion was chest pain and/or dyspnea in 66.8% of
examinations and 80-90% of MPIs were performed in
patients with known cardiac disease or symptoms consistent
with it. A median ERD of 121 mSv was noted for the sub-
group of 424 (38.6%) patients who underwent repeat MPI.
MPIs were repeated within 1 year in 117 (28%) patients.
Multivariate associations with multiple MPI included older
age and insurance status, with trends noted for male patients
and higher socioeconomic status. 
Conclusions: Performance of multiple MPI and other concur-
rent procedures requiring ionizing radiation is not
uncommon, and is associated with a high cumulative ERD
over a 20-year period.
Perspective: This study, which targeted MPI as an index
event, reinforces the previous observation that medical pro-
cedures may result in a significant, cumulative lifetime
exposure to potentially harmful ionizing radiation. While
the link between radiation exposure of this magnitude and
subsequent cancer risk is scientifically sound, an actual
increase in the burden of radiation-induced cancers in a
patient population of this age has yet to be demonstrated.
Furthermore, the balance of risk from radiation exposure to
benefit from diagnosis and more aggressive management of
ischemic heart disease has yet to be studied. These issues
should be the target of future investigations.  
Summary written by: William F. Armstrong, MD
Prevention/Vascular
Efficacy and Safety of More Intensive Lowering of
LDL Cholesterol: A Meta-Analysis of Data From
170,000 Participants in 26 Randomised Trials
Cholesterol Treatment Trialists’ (CTT) Collaboration
Lancet 2010;376:1670–1681.
Study Question: Is the low-density lipoprotein cholesterol
(LDL-C) “lower is better” hypothesis safe and effective? 
Methods: This was a meta-analysis of data from randomized
trials involving at least 1,000 participants and at least 2 years’
treatment duration of more versus less intensive statin regi-
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mens (five trials; 39,612 individuals; median follow-up 5.1
years) and of statin versus control (21 trials; 129,526 indi-
viduals; median follow-up 4.8 years). For each type of trial,
investigators calculated the average risk reduction and aver-
age risk reduction per 1.0 mmol/L LDL-C (equivalent to
38.7 mg/dl) reduction at 1 year after randomization.
Results: In the trials of more versus less intensive statin ther-
apy, the weighted mean further reduction in LDL-C at 1
year was 0.51 mmol/L. Compared with less intensive treat-
ments, more intensive regimens produced on average a 15%
further reduction in major vascular events, consisting of
separately significant reductions in coronary death or nonfa-
tal myocardial infarction of 13%, in coronary
revascularization of 19%, and in ischemic stroke of 16%
(each highly significant). The further reductions in risk per
1.0 mmol/L LDL-C were similar to the proportional
reductions in the trials of statin versus control. When both
types of trials were combined, similar proportional reduc-
tions in major vascular events per 1.0 mmol/L LDL-C
reduction were found in all types of patients studied (rate
ratio [RR] for all patients, 0.78; p < 0.0001), including
those with LDL-C lower than 2 mmol/L on the less inten-
sive or control regimen. Across all 26 trials, all-cause
mortality was reduced by 10% per 1.0 mmol/L LDL-C
reduction (p < 0.0001), largely reflecting significant reduc-
tions in deaths due to coronary heart disease and other
cardiac causes, with no significant effect on deaths due to
stroke or other vascular causes. No significant effects were
observed on deaths due to nonvascular causes or cancer
incidence, even at low LDL-C concentrations. There was a
lower risk in those at the upper versus lower tertile of high-
density lipoprotein cholesterol (HDL-C) regardless of the
on-treatment LDL-C or statin dosing.
Conclusions: Further reductions in LDL-C safely produce
definite further reductions in the incidence of heart attack,
revascularization, and ischemic stroke, with each 1.0
mmol/L reduction reducing the annual rate of these major
vascular events by just over one-fifth. There was no evidence
of any threshold within the cholesterol range studied, sug-
gesting that reduction of LDL cholesterol by 2-3 mmol/L
would reduce risk by about 40-50%. 
Perspective: These findings lend support to those who
believe in the ‘lower is better’ hypothesis. A few points of
clinical import: When considering the incremental value per
1 mmol/L decrease in LDL-C with more versus less
intense statin, the reduction in LDL-C applies regardless of
baseline LDL-C, and there is a significant benefit for those
with a baseline LDL-C <70 mg/dl even on the less intense
regimen. Very low levels of LDL-C are associated with a
reduced overall mortality with no increase in cancer risk,
and there is a residual increased risk despite very low LDL-
C levels associated with a low HDL-C.
Summary written by: Melvyn Rubenfire, MD
Safety of Anacetrapib in Patients With or at High
Risk for Coronary Heart Disease
Cannon CP, Shah S, Dansky HM, et al., on behalf of the DEFINE
Investigators.
N Engl J Med 2010;Nov 17:[Epub ahead of print].
Study Question: What are the side effects and overall safety pro-
file and the effects on lipid levels of anacetrapib in patients
with coronary heart disease (CHD) or risk factors for CHD?  
Methods: The DEFINE investigators conducted a randomized,
double-blind, placebo-controlled trial to assess the efficacy
and safety profile of anacetrapib in patients with CHD or at
high risk for CHD. Eligible patients who were taking a statin
and who had a low-density lipoprotein (LDL) cholesterol
level consistent with guideline recommendations received 100
mg of anacetrapib or placebo daily for 18 months. Primary
endpoints were the percent change from baseline in LDL
cholesterol at 24 weeks (high-density lipoprotein [HDL] cho-
lesterol level was a secondary endpoint) and the safety and
side effect profile of anacetrapib through 76 weeks.
Results: A total of 1,623 patients underwent randomization.
By 24 weeks, the LDL cholesterol level had been reduced
from 81 to 45 mg/dl in the anacetrapib group, as compared
with a reduction from 82 to 77 mg/dl in the placebo group
(p < 0.001)—a 39.8% reduction with anacetrapib beyond
that seen with placebo. In addition, the HDL cholesterol
level increased from 41 to 101 mg/dl with anacetrapib com-
pared with an increase from 40 to 46 mg/dl with placebo (p
< 0.001)—a 138.1% increase with anacetrapib beyond that
seen with placebo. Through 76 weeks, no changes were
noted in blood pressure or electrolyte or aldosterone levels
with anacetrapib compared with placebo. Prespecified adju-
dicated cardiovascular events occurred in 16 patients treated
with anacetrapib (2.0%) and 21 patients receiving placebo
(2.6%) (p = 0.40). The prespecified Bayesian analysis indi-
cated that this event distribution provided a predictive
probability (confidence) of 94% that anacetrapib would not
be associated with a 25% increase in cardiovascular events,
as seen with torcetrapib. 
Conclusions: Treatment with anacetrapib had robust effects on
LDL and HDL cholesterol, had an acceptable side effect pro-
file, and did not result in the adverse cardiovascular effects
observed with torcetrapib. 
Perspective: This moderate-size safety study shows that
anacetrapib, when used concomitantly with statin therapy,
had substantial effects on plasma lipid levels and an accept-
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able side effect profile. It remains to be seen whether further
reductions in LDL cholesterol levels, below the levels cur-
rently achieved with statins, and raising HDL cholesterol
levels will be of clinical benefit to patients. These results
should provide a rationale and impetus for conducting a
large clinical outcome trial in patients at high risk for car-
diovascular events.
Summary written by: Debabrata Mukherjee, MD
Association Between Implementation of a Medical
Team Training Program and Surgical Mortality
Neily J, Mills PD, Young-Xu Y, et al.
JAMA 2010;304:1693–1700.
Study Question: Is there an association between Veterans Health
Administration (VHA) medical team training and surgical
outcomes?  
Methods: A total of 184,409 cases were sampled from 108
VHA facilities. Seventy-four facilities required formalized
medical team training including mandated briefings and
debriefings (including checklists) in the operating room; the
remainder served as a contemporary control group. Medical
team training consisted of 2 months of preparation, a 1-day
conference, and 1 year of quarterly coaching interviews. The 
primary endpoint was mortality rates obtained from the
VHA Surgical Quality Improvement Program over fiscal
years 2006 to 2008. 
Results: There was an 18% reduction in annual mortality
(relative risk, 0.82; p = 0.01) in facilities that underwent
medical team training compared to a 7% decrease in those
facilities included in the study that did not. Propensity
matching, utilized to reduce potential confounding and
selection bias secondary to the nonrandomized assignment
of facilities to medical team training, revealed a decline of
50% in the risk-adjusted surgical mortality rate in the train-
ing group compared to the nontraining group. A
“dose-response” relationship of a reduction of 0.5 deaths per
1,000 procedures was noted for every additional quarter of
time in the training program (p = 0.001). 
Conclusions: Participation in the VHA medical team training
program was associated with a lower surgical mortality. 
Perspective: I personally believe the study’s conclusion because
it formalizes an informal process I have seen successful (and
safe) surgeons use throughout my career. I am troubled, how-
ever, about the need for sophisticated statistical analysis to
overcome some fundamental study design flaws, and that non-
medical team training hospitals also experience a decrease in
mortality over the same time period. Surely, a national ran-
domized controlled trial in non-VHA hospitals would be the
next logical step in determining if medical team training actu-
ally decreases surgical mortality.
Summary written by: John E. Rectenwald, MD
Effect of Celiprolol on Prevention of
Cardiovascular Events in Vascular Ehlers-Danlos
Syndrome: A Prospective Randomised, Open,
Blinded-Endpoints Trial
Ong KT, Perdu J, De Backer J, et al.
Lancet 2010;376:1476–1484.
Study Question: What is the impact of celiprolol on the inci-
dence of arterial dissections and ruptures in vascular
Ehlers-Danlos syndrome? 
Methods: The authors performed a multicenter, randomized,
open trial with blinded assessment of clinical events in eight
centers in France and one in Belgium. A total of 53 patients
with clinical vascular Ehlers-Danlos syndrome were randomly
assigned to 5 years of treatment with celiprolol or placebo.
Celiprolol was up-titrated every 6 months by increments of
100 mg to a maximum of 400 mg twice daily. The primary
endpoint was occurrence of arterial dissection or rupture.
Results: The study randomized 25 patients to celiprolol or 28
to control group. Mean duration of follow-up was 47
months, and the trial was stopped early for treatment benefit.
The primary endpoints occurred in five (20%) patients in the
celiprolol arm and in 14 (50%) controls (hazard ratio, 0.36;
95% confidence interval, 0.15-0.88; p = 0.040). Celiprolol
was associated with severe fatigue in one patient and mild
fatigue in two patients related to dose up-titration. 
Conclusions: Celiprolol is effective at reducing the occurrence
of vascular complications in patients with vascular Ehlers-
Danlos syndrome. 
Perspective: The authors are to be commended for successfully
completing a randomized trial to define the therapy for such a
rare disorder. Beyond the immediate implications for patients
with vascular Ehlers-Danlos syndrome, the study establishes a
paradigm for defining therapeutic strategies for similar
exceedingly rare diseases.
Summary written by: Hitinder S. Gurm, MBBS
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